Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Marco Loffi, Silvia Frattini, Marta Mazzotta, Chiara Bernelli, Gian B Danzi
No abstract text is available yet for this article.
September 21, 2023: Minerva cardiology and angiology
#2
REVIEW
Kelli Blackwell, Michele Blackwell, Thomas Blackwell
PURPOSE OF REVIEW: The purpose of this review is to analyze the link between testosterone replacement therapy (TRT) and adverse cardiovascular (CV) events. RECENT FINDINGS: A few published studies suggest a link between TRT and CV events. These studies contained flaws, and many other studies reveal a reduction in CV events. Hypogonadism is associated with increased mortality in men with CVD. TRT in hypogonadal men can improve many CVD risk factors, reduce QT interval prolongation, lead to better outcomes in heart failure patients, and slow the progression of atherosclerosis...
September 21, 2023: Current Cardiology Reports
#3
JOURNAL ARTICLE
Erberto Carluccio, Frank L Dini, Michele Correale, Giuseppe Dattilo, Michele Ciccarelli, Francesca Vannuccini, Stefano Sforna, Giuseppe Pacileo, Daniele Masarone, Laura Scelsi, Stefano Ghio, Carlo Gabriele Tocchetti, Valentina Mercurio, Natale Daniele Brunetti, Savina Nodari, Giuseppe Ambrosio, Alberto Palazzuoli
BACKGROUND: In patients with heart failure with reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan (S/V) may reverse left ventricular remodeling (rLVR). Whether this effect is superior to that induced by other renin-angiotensin system (RAS) inhibitors is not well known. METHODS: HFrEF patients treated with S/V (n = 795) were compared, by propensity score matching, with a historical cohort of 831 HFrEF patients (non-S/V group) treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (RAS inhibitors)...
September 21, 2023: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
#4
REVIEW
Daniel Addison, Tomas G Neilan, Ana Barac, Marielle Scherrer-Crosbie, Tochi M Okwuosa, Juan C Plana, Kerryn W Reding, Viviany R Taqueti, Eric H Yang, Vlad G Zaha
Advances in cancer therapeutics have led to dramatic improvements in survival, now inclusive of nearly 20 million patients and rising. However, cardiovascular toxicities associated with specific cancer therapeutics adversely affect the outcomes of patients with cancer. Advances in cardiovascular imaging have solidified the critical role for robust methods for detecting, monitoring, and prognosticating cardiac risk among patients with cancer. However, decentralized evaluations have led to a lack of consensus on the optimal uses of imaging in contemporary cancer treatment (eg, immunotherapy, targeted, or biological therapy) settings...
September 21, 2023: Circulation
#5
JOURNAL ARTICLE
Anna Kabłak-Ziembicka, Rafał Badacz, Michał Okarski, Magdalena Wawak, Tadeusz Przewłocki, Jakub Podolec
MicroRNAs are small non-coding post-translational biomolecules which, when expressed, modify their target genes. It is estimated that microRNAs regulate production of approximately 60% of all human proteins and enzymes that are responsible for major physiological processes. In cardiovascular disease pathophysiology, there are several cells that produce microRNAs, including endothelial cells, vascular smooth muscle cells, macrophages, platelets, and cardiomyocytes. There is a constant crosstalk between microRNAs derived from various cell sources...
2023: Archives of Medical Science: AMS
#6
JOURNAL ARTICLE
Muhammet Hamza Halil Toprak, Erkut Öztürk, Ali Can Hatemi, Alper Güzeltaş, İbrahim Cansaran Tanıdır
No abstract text is available yet for this article.
September 21, 2023: Anatolian Journal of Cardiology
#7
JOURNAL ARTICLE
Betül Öztürk, Mustafa Muhammed Güneyli Oğlu, Raziye Merve Yaradilmiş, Orkun Aydın, Deniz Yasar, Ali Güngör, I Lknur Bodur, Aytaç Göktuğ, I Lker Ufuk Sayici, Utku Arman Örün, Can Demir Karacan, Nilden Tuygun
INTRODUCTION: Cardiological emergencies are reported to constitute almost 15% of all emergency department visits. This study aimed to characterize the main signs and symptoms of the infants that necessitated pediatric cardiology consultation and to analyze the characteristics of patients diagnosed with a cardiological disorder. MATERIAL AND METHODS: Patients aged 1 month to 1 year who were consulted to the pediatric cardiology service during a 4-year period were retrospectively evaluated...
September 20, 2023: Postgraduate Medicine
#8
EDITORIAL
Bruno B Lima, Dominik C Benz
No abstract text is available yet for this article.
September 20, 2023: Journal of Nuclear Cardiology
#9
EDITORIAL
Theresa Reiter
No abstract text is available yet for this article.
September 20, 2023: Journal of Nuclear Cardiology
#10
JOURNAL ARTICLE
Karina Huynh
No abstract text is available yet for this article.
September 20, 2023: Nature Reviews. Cardiology
#11
JOURNAL ARTICLE
Julia E Behrend, Amy S Lay, Nicholas K Brown, Janelle R Bolden, Anna G Joong, Sandhya R Ramlogan
Congenital interventricular septal aneurysms (IVSA) of the muscular septum are rare and can be associated with other familial abnormalities of the ventricular septum, arrhythmias, additional congenital heart disease, and chromosomal abnormalities. IVSA is also linked to ventricular dysfunction and non-compaction, although there are limited reports of this association presenting in utero. We describe a case of fetal ventricular septal aneurysm associated with ventricular dysfunction and pericardial effusion.
September 20, 2023: Pediatric Cardiology
#12
JOURNAL ARTICLE
Cornelius Bohn, Thibault Schaeffer, Magdalena Cuman, Helena Staehler, Chiara Di Padua, Paul Philipp Heinisch, Nicole Piber, Alfred Hager, Peter Ewert, Jürgen Hörer, Masamichi Ono
OBJECTIVE: The purpose of this study is to evaluate the incidence and outcomes regarding tachyarrhythmia in patients after total cavopulmonary connection. METHODS: A retrospective analysis of 620 patients who underwent total cavopulmonary connection between 1994 and 2021 at our institution was performed. Incidence of tachyarrhythmia was depicted, and results after onset of tachyarrhythmia were evaluated. Factors associated with the onset of tachyarrhythmia were identified...
September 21, 2023: Cardiology in the Young
#13
EDITORIAL
Araba Ofosu-Somuah, Matthew A Cavender, George A Stouffer
No abstract text is available yet for this article.
September 18, 2023: American Journal of Cardiology
#14
EDITORIAL
Thierry Bové
No abstract text is available yet for this article.
September 18, 2023: American Journal of Cardiology
#15
JOURNAL ARTICLE
Mirvat Alasnag, Fayez Bokhari, Abdulrahman Almoghairi, Khaled Marri, Abdullah Alenezi, Waleed AlHarbi, Nouf Alanazi, Haitham Amin, Hussam Noor, Shereen Al-Shaikh, Fawaz Bardowli, Hatim Al Lawati, Khalid AlFaraidy, Mohammed AlShehri, Adel Tash, Waleed AlHabeeb, Mohammed Balghith, Michael Thabane, Lehana Thabane, Khaled Al-Shaibi
BACKGROUND: Severe mitral regurgitation (MR) with left ventricular dysfunction portends worse outcomes. Over the course of the last two decades, transcatheter repair of the mitral valve offered an alternative therapeutic modality for those deemed inoperable or high risk. Landmark studies such as the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation and Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation trials have shown conflicting results with respect to all-cause death and heart failure rehospitalisations...
September 20, 2023: BMJ Open
#16
JOURNAL ARTICLE
Chiwook Chung, Ah-Ram Kim, Il-Young Jang, Min-Woo Jo, Seongho Lee, Dongbum Kim, Hee Kwon, Do-Yoon Kang, Sei Won Lee
INTRODUCTION: Rehabilitation is well known to improve clinical symptoms and decrease the risk of mortality in patients with chronic respiratory or cardiovascular diseases. We will evaluate the efficacy of smartphone application-based rehabilitation programmes in patients with chronic respiratory or cardiovascular diseases. METHODS AND ANALYSIS: This single-centre single-blind randomised controlled trial will recruit a total of 162 participants from Asan Medical Center (81 patients each for pulmonary and cardiac rehabilitation, respectively)...
September 20, 2023: BMJ Open
#17
EDITORIAL
Jorge R Alegria, B Hadley Wilson, R Scott Wright
No abstract text is available yet for this article.
September 26, 2023: Journal of the American College of Cardiology
#18
REVIEW
Johan Verbeeck, Mickaël De Backer, Jan Verwerft, Samuel Salvaggio, Marco Valgimigli, Pascal Vranckx, Marc Buyse, Edgar Brunner
A time-to-first-event composite endpoint analysis has well-known shortcomings in evaluating a treatment effect in cardiovascular clinical trials. It does not fully describe the clinical benefit of therapy because the severity of the events, events repeated over time, and clinically relevant nonsurvival outcomes cannot be considered. The generalized pairwise comparisons (GPC) method adds flexibility in defining the primary endpoint by including any number and type of outcomes that best capture the clinical benefit of a therapy as compared with standard of care...
September 26, 2023: Journal of the American College of Cardiology
#19
REVIEW
Gemma A Figtree, Stephen T Vernon, Jason A Harmer, Michael P Gray, Clare Arnott, Eric Bachour, Giannie Barsha, David Brieger, Alex Brown, David S Celermajer, Keith M Channon, Nicholas W S Chew, James J H Chong, Clara K Chow, Peter A Cistulli, Patrick T Ellinor, Stuart M Grieve, Tomasz J Guzik, Emil Hagström, Alicia Jenkins, Garry Jennings, Anthony C Keech, Katharine A Kott, Leonard Kritharides, Mamas A Mamas, Roxana Mehran, Peter J Meikle, Pradeep Natarajan, Kazuaki Negishi, John O'Sullivan, Sanjay Patel, Peter J Psaltis, Julie Redfern, Philippe G Steg, David R Sullivan, Johan Sundström, Birgit Vogel, Andrew Wilson, Dennis Wong, Deepak L Bhatt, Jason C Kovacic, Stephen J Nicholls
Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is lacking. We assembled an international, multidisciplinary team to develop an evidence-based clinical pathway for SMuRFless CAD patients...
September 26, 2023: Journal of the American College of Cardiology
#20
EDITORIAL
Mary B Taylor
No abstract text is available yet for this article.
September 26, 2023: Journal of the American College of Cardiology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
